As multiple markers have demonstrated to be abnormal in patients with advanced liver disease compared with healthy volunteers, we sought to validate these markers by comparing levels in survivors and nonsurvivors at 3 months and then investigated the effect of targeted albumin infusions. Here, ALB is linked to liver disorder.